Tamoxifen vs Raloxifene for Gyno: Which SERM Works Better

When gynecomastia has already started, the drug class that actually shrinks it is the selective estrogen receptor modulator, not the aromatase inhibitor. The distinction is mechanical. An aromatase inhibitor lowers how much estradiol is made. A SERM sits in the estrogen receptor inside breast tissue and blocks it, so that whatever estradiol is circulating cannot signal the gland to grow. For prevention on a cycle, controlling estradiol is the right strategy. For a gland that is already tender and growing, blocking the receptor is what produces regression.

The evidence for this is clearest in prostate cancer, where the anti-androgen bicalutamide caused gynecomastia in 73% of men in a randomised trial. Tamoxifen at 20 mg daily cut that rate to 10%, while the aromatase inhibitor anastrozole left it at 51% (Boccardo, Journal of Clinical Oncology 2005), a difference that has made tamoxifen the standard for drug-induced gyno and relegated AIs to a supporting role. The same logic applies to steroid-induced gyno: fix estradiol with an AI so the problem does not recur, and treat the gland with a SERM.

Two SERMs dominate this use: tamoxifen and raloxifene. The tamoxifen vs raloxifene for gyno question comes up constantly because they are similar drugs with different histories, different dosing and slightly different side-effect profiles, and because the published data comparing them directly is thin but interesting.

Tamoxifen for gyno has the longest track record of any medical option. It has been used off-label for gynecomastia since the 1980s, and case series report partial or complete regression in most men treated during the proliferative phase, although a 2013 systematic review found no randomised trials, with the best results in glands under six months old and under about 4 cm. Pain and tenderness typically resolve within one to two weeks; visible size reduction takes four to eight weeks.

The standard dose of tamoxifen for gyno is 10 to 20 mg once daily. Twenty milligrams is the usual starting point for an active, tender gland; 10 mg is used for maintenance or for milder cases. Courses run from four weeks to three months. Longer courses do not add much, because a gland that has not responded by three months is unlikely to respond at all, it has either fibrosed or is being driven by something the SERM cannot address, such as prolactin.

Tamoxifen's pharmacology has two features worth knowing for this use. Its half-life is long, five to seven days for the parent drug, and its active metabolite endoxifen accumulates over weeks, so the effect builds and persists after stopping. And it is not purely an antagonist: in some tissues it acts as a weak estrogen, which is why it protects bone and, in men, raises SHBG and lowers IGF-1 during treatment, as shown in men on bicalutamide. The IGF-1 effect is the one bodybuilders notice.

The gyno from steroids guide covers where tamoxifen fits in an on-cycle prevention plan; this article is about treating tissue that already exists.

Raloxifene was developed as an osteoporosis drug for postmenopausal women and is licensed at 60 mg once daily for that purpose. Its use in gynecomastia is entirely off-label and rests on a smaller evidence base than tamoxifen's, but the evidence that exists is favourable. In the most-cited comparison, a paediatric series of adolescents with persistent pubertal gynecomastia, raloxifene at 60 mg produced some improvement in 91% of patients and a greater-than-50% reduction in gland size in 86%, against 86% and 41% with tamoxifen at 10 to 20 mg (Lawrence, Journal of Pediatrics 2004). The numbers were small and the study was retrospective, so the short summary is that raloxifene performed at least as well, not that it is proven superior.

The dose in adults is 60 mg daily; some clinicians use 120 mg for the first weeks in a resistant gland, but there is no controlled data for the higher dose. Timelines are similar to tamoxifen's: tenderness fades in one to two weeks, size changes over one to three months.

What sets raloxifene apart is its tissue selectivity. It is a more complete antagonist in breast tissue and a weaker agonist elsewhere, which is expected to give a smaller effect on IGF-1, a more neutral effect on lipids, and fewer of the mood and visual side effects occasionally reported with tamoxifen. Its half-life of about 27 hours means it clears within days of stopping, which some men prefer and which also means missed doses matter more. It is also, in most markets, several times the price of generic tamoxifen.

Set side by side, the two drugs differ less in whether they work than in how they fit the man taking them.

Tamoxifen for gyno is the sensible first choice for most men because of the evidence base, the price and the availability. Raloxifene is the better fit for a man who is concerned about IGF-1 suppression during a growth phase, who has lipid abnormalities he does not want worsened, who experienced mood or visual side effects on tamoxifen, or who simply wants a drug that clears quickly. Some clinicians reserve raloxifene for glands that did not respond to a full tamoxifen course; the logic is that a different SERM may succeed, though the more common reason for tamoxifen failure is fibrosis, which raloxifene cannot fix either.

Neither should be combined with a crashed estradiol. Men sometimes add a SERM on top of an aggressive AI dose, reasoning that more anti-estrogen is safer. It is not: the SERM already protects the gland, and the AI-induced low estradiol adds joint pain, libido loss and lipid damage for no benefit. Run estradiol in range with the AI and let the SERM do the gland work, the aromatase inhibitors side effects guide describes what the alternative looks like.

Both drugs share the class risk of venous thromboembolism. In the large breast cancer prevention trials, tamoxifen and raloxifene roughly doubled the rate of deep vein thrombosis and pulmonary embolism compared with placebo; the absolute risk in a healthy young man over a four-to-eight-week course is low, but a personal or family history of clotting, a known thrombophilia, recent surgery or immobility, or smoking should prompt a conversation with a physician before either is started. Neither should be used by anyone with a history of clots without specialist input.

Tamoxifen's specific issues are hot flushes, mood changes in a minority, nausea, occasional visual disturbance (a reason to stop and be examined), and the IGF-1 drop. Rare hepatotoxicity has been reported. Raloxifene's are hot flushes, leg cramps and, uncommonly, peripheral oedema. Both can cause a transient increase in tenderness in the first days as the gland responds.

In steroid-using men there is a further consideration. Tamoxifen raises LH and testosterone in men with functioning testes, which is why it is used in post-cycle therapy, and in a man still on cycle this is irrelevant, but in a man between cycles it changes the hormonal picture during the course. Raloxifene has a similar but weaker effect. Neither reliably lowers estradiol; a man who needs estradiol reduced needs an aromatase inhibitor as well, appropriately dosed. The best estrogen blocker for men ranking lays out how the classes combine.

Signs the SERM is not going to work and the gland needs a different plan:

For a man with new, tender gyno, the sequence that most physicians treating this off-label follow is straightforward. Confirm it is glandular tissue rather than fat, the gyno vs chest fat self-check covers this. Address the cause: correct estradiol with an appropriately dosed AI if on cycle or TRT, check prolactin on a 19-nor, stop a triggering medication where possible. Start tamoxifen for gyno at 20 mg daily, or raloxifene at 60 mg daily where the profile favours it. Expect tenderness to settle within two weeks. Reassess at four weeks; if the gland is shrinking, continue to eight to twelve weeks and then stop. If there is no change at four weeks, review the diagnosis and consider whether the tissue is fibrotic.

After stopping, some regression continues for several weeks as the drug clears. A small residual button is common and, if the trigger is controlled, stable. If it grows back, the trigger was not controlled, usually an estradiol that was never actually measured on a sensitive assay, and the fix is the estradiol, not another course.

Where a full course of either drug fails on tissue that was already firm, the realistic remaining option is surgical excision, which the does gyno go away guide discusses. Neither SERM is a substitute for the surgeon once the gland has fibrosed, and the most useful thing this comparison can do is get a man onto one of them before that happens.

Aromasin.org is an independent educational resource. We are not affiliated with Pfizer, any pharmaceutical manufacturer, or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.